Journal ArticleDOI
Engineering a bispecific antibody with a common light chain: Identification and optimization of an anti-CD3 epsilon and anti-GPC3 bispecific antibody, ERY974.
Hirotake Shiraiwa,Atsushi Narita,Mika Kamata-Sakurai,Takahiro Ishiguro,Yuji Sano,Naoka Hironiwa,Takashi Tsushima,Hiroaki Segawa,Toshiaki Tsunenari,Yosuke Ikeda,Yoko Kayukawa,Mizuho Noguchi,Tetsuya Wakabayashi,Akihisa Sakamoto,Hiroko Konishi,Taichi Kuramochi,Mika Endo,Kunihiro Hattori,Jun-ichi Nezu,Tomoyuki Igawa +19 more
Reads0
Chats0
TLDR
The outline, prospects, and limitations of the common light chain format, which includes one of Chugai's proprietary technologies, termed ART-Ig technology, are introduced and some tips for de-risking the antibody when engineering a T cell redirecting antibody are described.About:
This article is published in Methods.The article was published on 2019-02-01. It has received 34 citations till now.read more
Citations
More filters
Journal ArticleDOI
Bispecific antibodies: a mechanistic review of the pipeline.
TL;DR: The current bispecific antibody landscape is reviewed from a mechanistic perspective, including a comprehensive overview of the pipeline, to have the potential for novel functionalities that are not provided by mixtures of monoclonal antibodies.
Journal ArticleDOI
Design and Production of Bispecific Antibodies.
Qiong Wang,Yiqun Chen,Jaeyoung Park,Xiao Liu,Yifeng Hu,Tiexin Wang,Kevin S. McFarland,Michael J. Betenbaugh +7 more
TL;DR: Two common formats of bispecific antibodies on the market are the single-chain variable fragment (scFv)-based (no Fc fragment) antibody and the full-length IgG-like asymmetric antibody, which are focused on in this review.
Journal ArticleDOI
Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells.
William R. Strohl,Michael Naso +1 more
TL;DR: New formats and dosing paradigms for TRBAs and CAR-T cells are being developed in efforts to maximize efficacy and minimize toxicity, as well as to optimize use with both solid and hematologic tumors, both of which present significant challenges such as target heterogeneity and the immunosuppressive tumor microenvironment.
Journal ArticleDOI
Bispecific Antibodies: From Research to Clinical Application.
Jiabing Ma,Yicheng Mo,Menglin Tang,Junjie Shen,Qi Yanan,Zhao Wenxu,Yi Huang,Yanmin Xu,Cheng Qian +8 more
TL;DR: In this paper, the authors elaborate on the classic platforms, mechanisms, and applications of BsAbs, and they hope that this review can stimulate new ideas for the development of BSAbs and improve current clinical strategies.
Journal ArticleDOI
Glypican 3-Targeted Therapy in Hepatocellular Carcinoma.
Takahiro Nishida,Hiroaki Kataoka +1 more
TL;DR: The results of recent clinical trials targeting GPC3 in HCC are introduced, the latest knowledge regarding the role of GPC2 in H CC progression and clinical application targeting G PC3 are summarized.
References
More filters
Journal ArticleDOI
Making antibody fragments using phage display libraries
TL;DR: Using a random combinatorial library of the rearranged heavy and kappa light chains from mice immune to the hapten 2-phenyloxazol-5-one (phOx), diverse libraries of antibody fragments are displayed on the surface of fd phage and elicited many more pairings with strong binding activities.
Journal ArticleDOI
Emicizumab Prophylaxis in Hemophilia A with Inhibitors
Johannes Oldenburg,Johnny Mahlangu,Benjamin Kim,Christophe Schmitt,Michael U. Callaghan,Guy Young,Elena Santagostino,Rebecca Kruse-Jarres,Claude Negrier,Craig M. Kessler,Nancy Valente,Elina Asikanius,Gallia G. Levy,Jerzy Windyga,Midori Shima +14 more
TL;DR: Empicizumab prophylaxis was associated with a significantly lower rate of bleeding events than no proPHylaxis among participants with hemophilia A with inhibitors and resulted in a bleeding rate that was significantly lower by 79% than the rate with previous bypassing‐agent prophylum.
Journal ArticleDOI
Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis
Josée Golay,Luisella Zaffaroni,Thomas Vaccari,Thomas Vaccari,Manuela Lazzari,Manuela Lazzari,Gian Maria Borleri,Gian Maria Borleri,Sergio Bernasconi,Sergio Bernasconi,Francesco Tedesco,Francesco Tedesco,Alessandro Rambaldi,Alessandro Rambaldi,Martino Introna,Martino Introna +15 more
TL;DR: It is concluded that CDC and ADCC are major mechanisms of action of rituximab on B-cell lymphomas and that a heterogeneous susceptibility of different lymphoma cells to complement may be at least in part responsible for the heterogeneity of the response of different patients to ritUXimab in vivo.
Journal ArticleDOI
An efficient route to human bispecific IgG
A. M. Merchant,Zhenping Zhu,Zhenping Zhu,Yuan Jean,A. Goddard,Camellia W. Adams,L. G. Presta,Paul Carter +7 more
TL;DR: The engineered heavy chains retain their ability to support antibody-dependent cell-mediated cytotoxicity as demonstrated with an anti-HER2 antibody.
Journal ArticleDOI
Alternative molecular formats and therapeutic applications for bispecific antibodies.
TL;DR: Bispecific antibodies are on the cusp of coming of age as therapeutics more than half a century after they were first described and provide great opportunity to tailor the design of bispecific antibody to match the proposed mechanisms of action and the intended clinical application.